Table 1 Drugs with predicted beneficial effects.
From: Targeting the post-synaptic proteome has therapeutic potential for psychosis in Alzheimer Disease
Drug | Indication | Targets gene | Drug-target Action | Correlation Between Gene Knockdown Signature and AD + P PSD Protein Signature |
|---|---|---|---|---|
Fostamatinib | Chronic immune thrombocytopenia | AURKB | Inhibitor | Negative |
Maraviroc | CCR5-tropic HIV-1 infection | CCR5 | Antagonist | Negative |
Leronlimab | Investigated for the treatment of a number of cancers and HIV | CCR5 | Antagonist | Negative |
Ibalizumab | HIV-1 | CCR5 | Antagonist | Negative |
Procaine | Local anesthetic primarily in oral surgery | DNMT1 | Inhibitor | Negative |
Epigallocatechin Gallate | Investigated for the treatment of Hypertension and Diabetic Nephropathy. | DNMT1 | Inhibitor | Negative |
Pimecrolimus | Mild to moderate atopic dermatitis | MTOR | Potentiator | Positive* |
